



## Clinical trial results:

### Advances in the management of mandibular osteoradionecrosis: Pentoxifylline and Tocopherol as medical treatment.

#### Summary

EudraCT number	2014-004975-22
Trial protocol	ES
Global end of trial date	31 January 2017

#### Results information

Result version number	v1 (current)
This version publication date	19 September 2021
First version publication date	19 September 2021

#### Trial information

##### Trial identification

Sponsor protocol code	ORN-2014-16
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	VHIR
Sponsor organisation address	Passeig Vall Hebron 119-129, Barcelona, Spain, 08035
Public contact	Joaquin Lopez-Soriano, VHIR, 34 934894779, joaquin.lopez.soriano@vhir.org
Scientific contact	Maxillofacial Department, Oral and Maxillofacial Surgery Department of Vall d'Hebron Hospital, 34 620684875, miryam- martos@hotmail.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	31 January 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	31 January 2017
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

Healing of mandibular osteoradionecrosis in patients irradiated for head and neck cancer after treatment with Pentoxifylline and Tocopherol (PENTO)

Protection of trial subjects:

A mandibular TC was done if any suspects of clinical deterioration were detected. Antibiotic treatment was started in case of confirmation of an infection after microbiological examination of exudates

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 March 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Spain: 25
Worldwide total number of subjects	25
EEA total number of subjects	25

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	25
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

Number of subjects started	25
Number of subjects completed	25

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

After signing consent, a simple randomization was done, by giving a letter to the patient where the treatment groups was specified. Patient and clinicians knew at every moment the group to which the patient was assigned

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	PTX Tocopherol
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Pentoxifylline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral ingesta of 800 mg pentoxifylline (2x 400 mg tablets), daily, between 6 and 18 months

Investigational medicinal product name	Tocopherol
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1000 UI tocopherol (2x 400UI tablets +1x 200)UI tablet), daily, between 6 and 18 months

<b>Arm title</b>	Control no treatment
Arm description: -	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 1</b>	PTX Tocopherol	Control no treatment
Started	13	12
Completed	13	12

## Baseline characteristics

---

### Reporting groups

Reporting group title	Overall trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	25	25	
Age categorical			
Units: Subjects			
Adults (18-64 years)	14	14	
From 65-84 years	11	11	
Gender categorical			
Units: Subjects			
Female	5	5	
Male	20	20	

## End points

### End points reporting groups

Reporting group title	PTX Tocopherol
Reporting group description: -	
Reporting group title	Control no treatment
Reporting group description: -	

### Primary: Intraoral ulceration reduction

End point title	Intraoral ulceration reduction
End point description:	
End point type	Primary
End point timeframe:	
18 months	

End point values	PTX Tocopherol	Control no treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	12		
Units: square millimeter				
median (full range (min-max))	-100 (-108 to -50)	-2 (-21 to 0)		

### Statistical analyses

Statistical analysis title	Bone exposition
Comparison groups	PTX Tocopherol v Control no treatment
Number of subjects included in analysis	25
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.017
Method	t-test, 2-sided
Parameter estimate	Mean difference (final values)

### Secondary: Oral aperture

End point title	Oral aperture
End point description:	
End point type	Secondary

End point timeframe:

3 months

<b>End point values</b>	PTX Tocopherol	Control no treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	12		
Units: millimeter(s)				
median (full range (min-max))	25.0 (16.0 to 34.0)	27.5 (19.5 to 30.8)		

### Statistical analyses

<b>Statistical analysis title</b>	Oral aperture
Comparison groups	PTX Tocopherol v Control no treatment
Number of subjects included in analysis	25
Analysis specification	Post-hoc
Analysis type	superiority
P-value	= 0.161
Method	t-test, 2-sided

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All the study

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.1
--------------------	------

### Reporting groups

Reporting group title	Total adverse events
-----------------------	----------------------

Reporting group description: -

<b>Serious adverse events</b>	Total adverse events		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 25 (8.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	2 / 25 (8.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Total adverse events		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 25 (8.00%)		
Musculoskeletal and connective tissue disorders			
Osteonecrosis			
subjects affected / exposed	2 / 25 (8.00%)		
occurrences (all)	2		



## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported